@FiercePharma: Academic docs and biotechs partner with veterinarians to find cancer cures. More from FierceAnimalHealth | Follow @FiercePharma
@CarlyHFierce: Can Sprout's Addyi shrug off serious side effects? These blockbusters did. FiercePharmaMarketing article | Follow @CarlyHFierce
> Pfizer ($PFE) is under fire at Japan's health ministry, which says the U.S.-based multinational failed to report about 200 cases of serious side effects, including 6 deaths, over a 6-year period ending in 2014. Report
> Caraco Pharmaceutical, a U.S. subsidiary of India's Sun Pharma, was still required to give notice to production workers that they'd be laid off, even after the manufacturer was raided by U.S. regulators, a court found. Report
> India's Dr. Reddy's Laboratories ($RDY) is reshuffling its top management after the departure of its North American chief, Umang Vora. Report
> South Africa-based Adcock Ingram plans to sell off an underperforming Indian unit, Cosme Farm Laboratories, after two years of writedowns. Report
> Slovenia-based drugmaker Krka saw profits climb 5% for the second quarter as strong sales in Western Europe made up for weaker performance in Russia. Report
> Two workers at a Gedeon Richter plant in Budapest were injured in an explosion. Report
Medical Device News
@FierceMedDev: Israeli nitric oxide drug-device player files for up to $36M Nasdaq IPO. Article | Follow @FierceMedDev
@VarunSaxena2: Providence Medical receives $12M in financing to expand sales of its spinal fusion devices. Story | Follow @VarunSaxena2
@EmilyWFierce: Recipharm strikes development deal for RedHill's bacteria-fighter candidate. FierceCRO item | Follow @EmilyWFierce
> Greatbatch grabs Lake Regional Medical for $730M to expand surgical offerings. News
> Abbott denies FT report that it's preparing $25B bid for St. Jude Medical. Article
Biotech News
@FierceBiotech: UCSF cardiology chief builds a case for two new targets for heart drugs. FierceBiotechResearch article | Follow @FierceBiotech
@JohnCFierce: I'm happy to see $MDVN back in a late-stage development race. It's been awhile, and they're smart, aggressive players. More from FiercePharmaMarketing | Follow @JohnCFierce
> J&J positions blockbuster contender daratumumab for a multiple myeloma showdown. Report
> Repatha OK looming, analysts wait to see if Amgen will start PCSK9 price war. More
> Novo Nordisk defers dream of expanding Victoza label after PhIII falls short. Story
> MorphoSys trades assets with Immatics to bolster I-O ambitions. Article
Vaccines News
> Pfizer's Trumenba shows 'robust' MenB protection in two PhIII trials. News
> Valneva licenses EB66 technology to develop human, veterinary vaccines. Report
> Takeda expands vaccine platform rights with Nanotherapeutics agreement. More
> FluGen reels in $12M to fund PhI of its universal flu jab. Story
> Scripps Research Institute, J&J test 'universal' flu vaccine in mice, monkeys. Article
CRO News
> WuXi inks lab testing pact with Chinese Lee's Pharm. News
> Germany lists 54 GVK suspensions as EU comes down on Indian CRO. More
> Recipharm strikes development deal for RedHill's bacteria-fighter candidate. Report
> CRO field to grow nearly 10% annually through 2019, report says. Story
> India's Accutest Research Labs expands into Latin America. Article
Pharma Manufacturing News
> Shire works deal with Sanquin so it can boost production of rare disease drug. More
> Woodcock says FDA will keep new plant quality grades a secret. Report
> Sterilization specialist on expansion streak. Item
> Sucampo gets control of Amitiza production in deal for Japanese company. Story
> Novo picks Clayton, NC, for its first U.S. API plant. Article
Pharma Asia News
> India's Gujarat state moves closer to country's first medical device testing lab. Story
> China's Shenzhen Hepalink keeps N. American deal stream rolling with Cytovance. More
> Oncology trials in China may see pilot program for 60-day IND decision. Story
> BD Life Science buys Silicon Valley-based Cellular Research, part of Decheng portfolio. Article
> Japan's PAFSC to review application from Takeda on glatiramer this week. Item
And Finally... Johnson & Johnson ($JNJ) sold off its Splenda brand sweetener as part of its ongoing strategy to focus in on key consumer health product lines. Report